Abstract
Ajulemic acid (CT-3, IP-751,1’,1’-dimethylheptyl-Δ8 acid) (AJA) has a cannabinoid-derived structure; however, there is no evidence that it produces psychotropic actions when given at therapeutic doses. In a variety of animal assays, AJA shows efficacy in models for pain and inflammation. Furthermore, in the rat adjuvant arthritis model, it displayed a remarkable action in preventing the destruction of inflamed joints. A phase-2 human trial with chronic, neuropathic pain patients suggested that AJA could become a useful drug for treating this condition. Its low toxicity, particularly its lack of ulcerogenicity, further suggests that it will have a highly favorable therapeutic index and may replace some of the current anti-inflammatory/analgesic medications. Studies to date indicate a unique mechanism of action for AJA that may explain its lack of adverse side effects.
Similar content being viewed by others
References
Burstein S. Therapeutic Potential of Ajulemic Acid (CT-3): In: Grontenhermen F, Russo E, eds.Cannabis and Cannabinoids. Binghamton, NY: Haworth Press Inc; 2002;381–388.
Burstein SH. Ajulemic acid (CT3): a potent analog of the acid metabolites of THC.Curr Pharm Des. 2000;6:1339–1345.
Burstein SH. The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential.Pharmacol Ther. 1999;82:87–96.
Burstein SH, Karst M, Schneider U, Zurier RB. Ajulemic acid: a novel cannabinoid produces analgesia without a “high”.Life Sci. 2004;75:1513–1522.
Burstein S, Hunter SA, Latham V, Renzulli L. A major metabolite of delta 1-tetrahydrocannabinol reduces its cataleptic effect in mice.Experientia. 1987;43:402–403.
Burstein S, Shoupe TS. Metabolic pathways for the transformation of delta 1-tetrahydrocannabinol in mouse hepatic microsomes.Drug Metab Dispos. 1981;9:94–96.
Burstein S, Rosenfeld J, Wittstruck T. Isolation and characterization of two major urinary metabolites of 1-tetrahydrocannabinol.Science. 1972;176:422–423.
Burstein SH, Kupfer D. Hydroxylation of trans-1-tetrahydrocannabinol by a hepatic microsomal monooxygenase.Chem Biol Interact. 1971;3:316.
Burstein SH, Menezes F, Williamson E, Mechoulam R. Metabolism of delta 1(6)-tetrahydro-cannabinol, an active marihuana constituent.Nature, 1970;225:87–88.
Perez-Reyes M. Pharmacodynamics of certain drugs of abuse. In: Barnett G, Chang CN, eds.Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs. Foster City, CA: Biomedical Publishers; 1985;287–310.
Burstein S, Hunter SA, Latham V, Renzulli L. Prostaglandins and cannabis-XVI. Antagonism of delta 1-tetrahydrocannabinol action by its metabolites.Biochem Pharmacol. 1986;35:2553–2558.
Burstein SH, Hull K, Hunter SA, Latham V. Cannabinoids and pain responses: a possible role for prostaglandins.FASEB J. 1988;2:3022–3026.
Burstein SH, Audette CA, Doyle SA, Hull K, Hunter SA, Latham V. Antagonism to the actions of platelet activating factor by a non-psychoactive cannabinoid.J Pharmacol Exp Ther. 1989;251:531–535.
Doyle SA, Burstein SH, Dewey WL, Welch SP. Further studies on the antinociceptive effects of delta 6-THC-7-oic acid.Agents Actions. 1990;31:157–163.
Burstein SH, Audette CA, Breuer A, et al. Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities.J Med Chem. 1992;35: 3135–3141.
Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.JAMA. 2003;290: 1757–1762.
Rhee MH, Vogel Z, Barg J, et al. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.J Med Chem. 1997;40:3228–3233.
Compton DR, Rice KC, De Costa BR, et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.J Pharmacol Exp Ther. 1993;265:218–226.
Recht LD, Salmonsen R, Rosetti R, et al. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid.Biochem Pharmacol. 2001;62:755–763.
Hunter SA, Burstein SH. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis.Life Sci. 1997;60:1563–1573.
Stebulis JA, Burstein SH, Torres R, et al. Ajulemic Acid, an antiinflammatory nonpsychoactive cannabinoid acid, modulates activation of human synovial cells. Paper presented at: 2004 Symposium on the Cannabinoids. June 20, 2004; Paestum, Italy.
Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA, Burstein SH. Dimethylheptyl-THC-11-oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure.Arthritis Rheum. 1998;41:163–170.
Dajani EZ, Larsen KR, Taylor J, et al. 1′,1′-Dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties.J Pharmacol Exp Ther. 1999;291:31–38.
Burstein SH, Friderichs E, Kogel B, Schneider J, Selve N. Analgesic effects of 1′,1′ dimethylheptyl-delta8-THC-11-oic acid (CT3) in mice.Life Sci. 1998;63:161–168.
Bidinger B, Torres R, Rossetti RG, et al. Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes.Clin Immunol. 2003;108:95–102.
Liu J, Li, H, Burstein SH, Zurier RB, Chen JD. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid.Mol Pharmacol. 2003;63:983–992.
Zurier RB, Rossetti RG, Burstein SH, Bidinger B. Suppression of human monocyte interleukin-1 beta production by ajulemic acid, a nonpsychoactive cannabinoid.Biochem Pharmacol. 2003;65:649–655.
Walker JM, Owen K, Petros P, Huang SM. Antiallodynic and analgesic actions of ajulemic acid reversed by a cannabinoid antagonist. Paper presented at: Society of Neuroscientists; November 9, 2000; New Orleans, LA.
Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis.Arthritis Rheum. 2004;50:985–998.
Burstein SH, Zurier RB. Pain reduction and lack of psychotropic effects with ajulemic acid: comment on the article by Sumariwalla et al.Arthritis Rheum. 2004;50:4078–4080.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published: June 29, 2005
Rights and permissions
About this article
Cite this article
Burstein, S. Ajulemic acid (IP-751): Synthesis, proof of principle, toxicity studies, and clinical trials. AAPS J 7, 15 (2005). https://doi.org/10.1208/aapsj070115
Received:
Accepted:
DOI: https://doi.org/10.1208/aapsj070115